Audit: QRS - Dry Fasting for Health & Longevity
Audit conducted on 30/09/2026 15:46 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 89 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Checked every lede sentence, protocol/time cell, tier item, gate item, marker row, cadence and qualitative item against the ER; each traces to ER text (e.g., time_1 to Practical Considerations line 427 and Expected Benefits line 163; action_3 to Therapeutic Protocol line 396). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | ER cautious phrasing carried over: “durability after the fasting month is unknown” (time_2_sub, ER line 169), “studied only as a supervised five-day protocol” (action_3_sub, ER line 396), “largely unexamined” (lede, ER line 493). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; contraindication thresholds and qualifiers match ER lines 363-372. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from ER “Populations who should avoid” (lines 361-372); Key Interactions from the ER interaction bullets (lines 345-359); modifying factors are not surfaced as risks or cautions. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, study citations, NCT IDs, expert names or brand names appear in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted tone mirrors the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-based while accessible; frames daytime dry fasting as tolerable without alarmism. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presented as condensed evidence, not orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No clinical-advice phrasing; items are stated as facts. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content presents information; no recommending or advising verbs. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No direct address of the reader. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language used; unavoidable technical terms are the ER’s own labels (e.g., “NSAIDs”, “NYHA class III–IV”), with lay glosses where the ER provides them (“thrombophilia (inherited clotting tendency)”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Items are terse fragments; cadence is a single compact sentence. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content (protocol variants, markers with optimal ranges, interaction gates) serves proactive, risk-aware adults. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents demanding protocols (29–30-day fasting month, lab monitoring cadence) for a willing audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not framed for the general population; optimal-range targets and detailed gates are included. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting follows the ER: modest daytime benefits, high-risk multi-day fasting, hypoglycemia on glucose-lowering drugs as the top risk. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Lede frames usage as “promoted for longevity”; no “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial route-of-administration or consumer-grade terms; “diabetes medicines” and “dangerously low blood sugar” follow the ER Conclusion (line 491). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed headings, gate headings, tier labels and table headers are unchanged (QRS lines 440, 477, 519, 539, 556, 582, 597-608, 775). |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template span variables are present; marker_# and qualitative_item_# expanded to marker_1..14 and qualitative_item_1..7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows only variable content changes; website spans, footer, CSS and structure unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No ER section mapped to a non-tiered QRS section is empty; empty tiers (Benefits High, Risks Speculative) are hidden per 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels used verbatim for protocol cells (“Dawn-to-dusk intermittent dry fasting (Ramadan model)”, “Eating-window structure”, “Prolonged dry fasting”) and interaction items. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels are the ER’s own labels or biomarker names; time-to-effect labels name the ER outcomes (weight and waist, blood pressure, well-being and mindfulness). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators; ER tier emojis and “⚠️ Conflicted” flags stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to terse items; parentheticals trimmed (e.g., eGFR units, NYHA definition, drug-class glosses) and no section is extended beyond the ER content. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata HTML comment is line 2, directly after “<!doctype html>”. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by “—” on lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside an HTML comment; not surfaced elsewhere. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only duration “00:02” is quoted, which contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: dry_fasting_2026-0930-1319_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.29 matches QRS.md version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0930-1521 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5.5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5.5” = nickname + version. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: dry_fasting_2026-0930-1319_Opus_QRS.html matches the file. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; quoting only where a colon requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Dry Fasting for Health & Longevity - Quick Reference Sheet” (line 22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Dry Fasting for Health & Longevity” (line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/30/2026 matches 2026-0930-1521. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | No additional header content. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens by defining the intervention as going without food and all fluids and naming it “a religious practice also promoted for longevity” before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 489-493): modest short-lived benefits, main costs, no added benefit from removing water, multi-day fasting high-risk. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words (script count). |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to ER passages: definition (line 489), longevity marketing (line 144), benefits and costs (lines 489-491), no added benefit (line 489), multi-day risk (line 493). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist terms in the lede. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trials cited. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER Key Interactions & Contraindications (lines 343-372). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All ten ER “Populations who should avoid” items represented (lines 542-551). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No trailing explanations; the pregnancy item’s placental-weight rationale and citation were stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds preserved: HbA1c above 9%, 3-month windows, CKD stage 3b–5 (eGFR below 45), NYHA III–IV, uric acid above 8 mg/dL, BMI below 18.5, age 75, 24 hours. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation used in the ER contraindications; none carried into the QRS. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated, consistent with the ER naming avoidance populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | Section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER Key Interactions & Contraindications (lines 345-359). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 14 non-contraindicated ER interactions listed; Lithium excluded because “Lithium therapy” is a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity words, mechanisms and mitigations after the dashes stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved (e.g., glimepiride, gliclazide, glyburide; amoxicillin, levetiracetam) and the vitamin C threshold (above 1 g daily) kept. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation in the ER interactions; none carried into the QRS. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated, consistent with the ER listing interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | Section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from ER Therapeutic Protocol (lines 390-405). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Covers the most-studied daily regimen, eating-window structure and prolonged dry fasting. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides more than three actionable aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans populated from ER lines 392, 396 and 398. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Weight and waist, blood pressure, well-being and mindfulness are the ER’s timed outcomes. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered Medium (weight, blood pressure) before Low (well-being and mindfulness). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three time-to-effect aspects exist in the ER. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans populated from ER lines 163, 169, 201-203 and 427. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from ER Expected Benefits (lines 151-221). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit variables present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are ER headings only, without effect sizes or qualifiers. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content retained. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high has no ER items and is set to display: none (line 521). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from ER Potential Risks & Side Effects (lines 236-330). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk variables present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are ER headings only (1 High, 3 Medium, 10 Low). |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content retained. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_speculative has no ER items and is set to display: none (line 593). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from ER Monitoring Protocol & Defining Success (lines 443-463). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 13 ER table biomarkers listed, plus the measured body weight/waist success criterion from ER line 447. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated from ER lines 445-447. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from ER Qualitative markers (lines 465-473). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven qualitative markers listed verbatim. |
Issues 30/09/2026 15:46
Pass rate 100.00%. No issues found.
Issues 30/09/2026 15:43
- 2.7 — Unnecessary jargon without gloss: marker_10_why uses “Hemoconcentration” (line 718) and stop_items uses “known thrombophilia” (line 546), although the ER provides plain-language glosses (thickening of blood as plasma water falls; inherited clotting tendency).
Fixes 30/09/2026 15:43
- 2.7 — Plain-language jargon replacement: Changed marker_10_why from “Hemoconcentration” to “Blood thickening from dehydration” and added the ER gloss “(inherited clotting tendency)” after “known thrombophilia” in stop_items.
Issues 30/09/2026 15:39
- 4.2 / 4.3 — NSAIDs label abbreviated: The Key Interactions item at line 563 reads “NSAIDs (ibuprofen, naproxen, high-dose aspirin)”, dropping the non-parenthetical qualifier “over-the-counter” from the ER bold label “NSAIDs (nonsteroidal anti-inflammatory drugs), over-the-counter (ibuprofen, naproxen, high-dose aspirin)” (ER line 350).
Fixes 30/09/2026 15:39
- 4.2 / 4.3 — NSAIDs label restored: Changed the Key Interactions item from “NSAIDs (ibuprofen, naproxen, high-dose aspirin)” to “NSAIDs, over-the-counter (ibuprofen, naproxen, high-dose aspirin)” to restore the ER bold label qualifier.
Issues 30/09/2026 15:36
- 1.1 — Unsupported body-composition target: Monitoring row 14 (line 759) gives “Improved” as the target for “Body weight, waist and body composition”, but the ER success criterion (line 447) names only improved weight, waist and blood pressure; body composition is only a baseline measurement.
Fixes 30/09/2026 15:36
- 1.1 — Unsupported body-composition target: Changed the Monitoring row 14 target from “Improved” to “Improved weight and waist”, matching the ER success criterion (ER line 447).
Issues 30/09/2026 15:32
- 14.2 — Body composition marker omitted: The ER Monitoring section (line 445) names body composition as a baseline measure, but the QRS Monitoring table (marker_14, line 756) lists only “Body weight and waist”.
Fixes 30/09/2026 15:32
- 14.2 — Body composition marker added: Changed marker_14_name from “Body weight and waist” to “Body weight, waist and body composition” to cover the ER Monitoring baseline measure.
Issues 30/09/2026 15:30
- 4.5 — Content overflows one A4 page: With 10 contraindications, 14 interactions, 14 monitoring rows and 7 qualitative items, the sheet exceeds one A4 page, yet the ~75-word near-verbatim cadence (line 769) and long protocol/time sub-lines (lines 461, 489, 511) were not condensed.
Fixes 30/09/2026 15:30
- 4.5 — Condensed overflowing text blocks: Shortened the monitoring cadence from ~75 to ~55 words and trimmed the action_2, time_1 and time_3 sub-lines to their key facts; all required gate items, markers and qualitative items were kept, so the sheet may still exceed one A4 page.
Issues 30/09/2026 15:23
- 7.2 — Key medication risk omitted: The at_a_glance text (line 433) leaves out the ER Conclusion’s key point (line 491) that dangerously low blood sugar threatens people taking certain diabetes medicines, which is the only High-tier risk.
Fixes 30/09/2026 15:23
- 7.2 — Key medication risk added: Added “on certain diabetes medicines, dangerously low blood sugar” to at_a_glance (ER Conclusion line 491), and tightened the wording elsewhere so it stays within 70 words (“a religious tradition also promoted for health and longevity” → “a religious practice also promoted for longevity”; “fasting that allows water” → “water-permitted fasting”).